Multivariate network meta-analysis of survival function parameters.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Author(s): Cope S;Cope S; Chan K; Chan K; Jansen JP; Jansen JP; Jansen JP
  • Source:
    Research synthesis methods [Res Synth Methods] 2020 May; Vol. 11 (3), pp. 443-456. Date of Electronic Publication: 2020 Apr 13.
  • Publication Type:
    Journal Article
  • Language:
  • Additional Information
    • Source:
      Publisher: Wiley Blackwell Country of Publication: England NLM ID: 101543738 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1759-2887 (Electronic) Linking ISSN: 17592879 NLM ISO Abbreviation: Res Synth Methods Subsets: MEDLINE
    • Publication Information:
      Publication: : Chichester : Wiley Blackwell
      Original Publication: Malden, MA : John Wiley & Sons, 2010-
    • Subject Terms:
    • Abstract:
      Background: Network meta-analysis (NMA) of survival data with a multidimensional treatment effect has been introduced as an alternative to NMA based on the proportional hazards assumption. However, these flexible models have some limitations, such as the use of an approximate likelihood based on discrete hazards, rather than a likelihood for individual event times. The aim of this article is to overcome the limitations and present an alternative implementation of these flexible NMA models for time-to-event outcomes with a two-step approach.
      Methods: First, for each arm of every randomised controlled trial (RCT) connected in the network of evidence, reconstructed patient data are fit to alternative survival distributions, including the exponential, Weibull, Gompertz, log-normal, and log-logistic. Next, for each distribution, its scale and shape parameters are included in a multivariate NMA to obtain time-varying estimates of relative treatment effects between competing interventions.
      Results: An illustrative analysis is presented for a network of RCTs evaluating multiple interventions for advanced melanoma regarding overall survival. Alternative survival distributions were compared based on model fit criteria. Based on the log-logistic distribution, the difference in shape and scale parameters for each treatment versus dacarbazine (DTIC) was identified and the corresponding log hazard and survival curves were presented.
      Conclusions: The presented two-step NMA approach provides an evidence synthesis framework for time-to-event outcomes grounded in standard practice of parametric survival analysis. The method allows for a more transparent and efficient model selection process.
      (© 2020 John Wiley & Sons, Ltd.)
    • References:
      Latimer NR. Survival analysis for economic evaluations alongside clinical trials-extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Making. 2013;33(6):743-754.
      Latimer N. NICE DSU Technical Support Document 14: Undertaking survival analysis for economic evaluations alongside clinical trials-extrapolation with patient-level data. 2011.
      Ouwens MJ, Philips Z, Jansen JP. Network meta-analysis of parametric survival curves. Res Synth Meth. 2010;1(3-4):258-271.
      Jansen JP. Network meta-analysis of survival data with fractional polynomials. BMC Med Res Methodol. 2011;11:61.
      Guyot P, Ades A, Ouwens M, Welton N. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.
      Guyot P, Welton NJ, Ouwens MJ, Ades AE. Survival time outcomes in randomized, controlled trials and meta-analyses: the parallel universes of efficacy and cost-effectiveness. Value Health. 2011;14(5):640-646.
      Achana FA, Cooper NJ, Bujkiewicz S, et al. Network meta-analysis of multiple outcome measures accounting for borrowing of information across outcomes. BMC Med Res Methodol. 2014;14:92.
      Jansen JP, Cope S. Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes. BMC Med Res Methodol. 2012;12:152.
      Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol. 2004;22(6):1118-1125.
      Bajetta E, Di Leo A, Zampino MG, et al. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol. 1994;12(4):806-811.
      Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17(9):2745-2751.
      Chiarion Sileni V, Nortilli R, Aversa SM, et al. Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. Melanoma Res. 2001;11(2):189-196.
      Cocconi G, Bella M, Calabresi F, et al. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med. 1992;327(8):516-523.
      Falkson CI, Falkson G, Falkson HC. Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol. 1991;9(8):1403-1408.
      Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an eastern cooperative oncology group study. J Clin Oncol. 1998;16(5):1743-1751.
      Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18(1):158-166.
      Thomson DB, Adena M, McLeod GR, et al. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. Melanoma Res. 1993;3(2):133-138.
      Young AM, Marsden J, Goodman A, Burton A, Dunn JA. Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma. Clin Oncol. 2001;13(6):458-465.
      Dempster AP. The direct use of likelihood for significance testing. Stat Comput. 1997;7(4):247-252.
      Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A. Bayesian measures of model complexity and fit. J R Stat Soc B Stat Methodology. 2002;64(4):583-639.
      Cope S, Ouwens MJ, Jansen JP, Schmid P. Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: a network meta-analysis with parametric survival models. Value Health. 2013;16(2):403-417.
      Dias S, Ades AE. Absolute or relative effects? Arm-based synthesis of trial data. Res Synth Meth. 2016;7(1):23-28.
      Riley RD, Price MJ, Jackson D, et al. Multivariate meta-analysis using individual participant data. Res Synth Methods. 2015;6(2):157-174.
      Keith BGD. Iterative generalized least squares for meta-analysis of survival data at multiple times. Biometrics. 1994;50(4):989-1002.
      Arends LR, Hunink MG, Stijnen T. Meta-analysis of summary survival curve data. Stat Med. 2008;27(22):4381-4396.
      Jackson D, Rollins K, Coughlin P. A multivariate model for the meta-analysis of study level survival data at multiple times. Res Synth Meth. 2014;5(3):264-272.
      Weir IR, Tian L, Trinquart L. Multivariate meta-analysis model for the difference in restricted mean survival times. Biostatistics. 2019.
      Barrett JK, Farewell VT, Siannis F, Tierney J, Higgins JP. Two-stage meta-analysis of survival data from individual participants using percentile ratios. Stat Med. 2012;31(30):4296-4308.
      Gasparrini A, Armstrong B. Multivariate meta-analysis: a method to summarize non-linear associations. Stat Med. 2011;30(20):2504-2506. discussion 2509-2510.
      Gasparrini A, Armstrong B, Kenward MG. Multivariate meta-analysis for non-linear and other multi-parameter associations. Stat Med. 2012;31(29):3821-3839.
      Jansen JP, Cope S. Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes. BMC Med Res Methodol. 2012;12(1):152-152.
      Jackson C, Stevens J, Ren S, et al. Extrapolating survival from randomized trials using external data: a review of methods. Med Decis Making. 2017;37(4):377-390.
      Royston P, Parmar MK. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med. 2002;21(15):2175-2197.
      Cope S, Jansen JP. Quantitative summaries of treatment effect estimates obtained with network meta-analysis of survival curves to inform decision-making. BMC Med Res Methodol. 2013;13:147.
    • Contributed Indexing:
      Keywords: evidence synthesis; multivariate methods; network meta-analysis; survival; time-to-event
    • Accession Number:
      7GR28W0FJI (Dacarbazine)
    • Publication Date:
      Date Created: 20200304 Date Completed: 20210615 Latest Revision: 20210615
    • Publication Date:
    • Accession Number:
    • Accession Number: